vs
1stdibs.com, Inc.（DIBS）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是1stdibs.com, Inc.的1.3倍（$30.3M vs $23.0M），1stdibs.com, Inc.净利率更高（-4.5% vs -221.3%，领先216.8%），REGENXBIO Inc.同比增速更快（43.0% vs 0.9%），1stdibs.com, Inc.自由现金流更多（$3.6M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 2.0%）
1stdibs.com, Inc.是一家美国电商企业，运营线上奢侈品交易平台，主营室内设计高端家具、艺术藏品、珠宝等高端商品。品牌最初创立于巴黎，现总部设于纽约，凭借推动古董行业迈入21世纪的创新举措获得业内认可。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
DIBS vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.3倍
$23.0M
营收增速更快
RGNX
高出42.1%
0.9%
净利率更高
DIBS
高出216.8%
-221.3%
自由现金流更多
DIBS
多$56.4M
$-52.8M
两年增速更快
RGNX
近两年复合增速
2.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.0M | $30.3M |
| 净利润 | $-1.0M | $-67.1M |
| 毛利率 | 73.5% | — |
| 营业利润率 | -10.1% | -190.0% |
| 净利率 | -4.5% | -221.3% |
| 营收同比 | 0.9% | 43.0% |
| 净利润同比 | 80.0% | -31.2% |
| 每股收益（稀释后） | $-0.02 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DIBSRGNX
| Q4 25 | $23.0M | $30.3M | ||
| Q3 25 | $22.0M | $29.7M | ||
| Q2 25 | $22.1M | $21.4M | ||
| Q1 25 | $22.5M | $89.0M | ||
| Q4 24 | $22.8M | $21.2M | ||
| Q3 24 | $21.2M | $24.2M | ||
| Q2 24 | $22.2M | $22.3M | ||
| Q1 24 | $22.1M | $15.6M |
净利润DIBSRGNX
| Q4 25 | $-1.0M | $-67.1M | ||
| Q3 25 | $-3.5M | $-61.9M | ||
| Q2 25 | $-4.3M | $-70.9M | ||
| Q1 25 | $-4.8M | $6.1M | ||
| Q4 24 | $-5.2M | $-51.2M | ||
| Q3 24 | $-5.7M | $-59.6M | ||
| Q2 24 | $-4.4M | $-53.0M | ||
| Q1 24 | $-3.3M | $-63.3M |
毛利率DIBSRGNX
| Q4 25 | 73.5% | — | ||
| Q3 25 | 74.3% | — | ||
| Q2 25 | 71.8% | — | ||
| Q1 25 | 72.4% | — | ||
| Q4 24 | 72.3% | 70.2% | ||
| Q3 24 | 71.0% | 48.8% | ||
| Q2 24 | 71.7% | 52.5% | ||
| Q1 24 | 72.5% | 72.6% |
营业利润率DIBSRGNX
| Q4 25 | -10.1% | -190.0% | ||
| Q3 25 | -21.3% | -176.3% | ||
| Q2 25 | -25.8% | -296.3% | ||
| Q1 25 | -27.7% | 13.6% | ||
| Q4 24 | -30.6% | -242.1% | ||
| Q3 24 | -34.9% | -256.6% | ||
| Q2 24 | -29.2% | -251.3% | ||
| Q1 24 | -24.3% | -408.8% |
净利率DIBSRGNX
| Q4 25 | -4.5% | -221.3% | ||
| Q3 25 | -16.0% | -208.3% | ||
| Q2 25 | -19.5% | -331.8% | ||
| Q1 25 | -21.3% | 6.8% | ||
| Q4 24 | -22.9% | -241.3% | ||
| Q3 24 | -26.8% | -246.3% | ||
| Q2 24 | -20.0% | -237.7% | ||
| Q1 24 | -15.0% | -405.4% |
每股收益（稀释后）DIBSRGNX
| Q4 25 | $-0.02 | $-1.30 | ||
| Q3 25 | $-0.10 | $-1.20 | ||
| Q2 25 | $-0.12 | $-1.38 | ||
| Q1 25 | $-0.14 | $0.12 | ||
| Q4 24 | $-0.14 | $-0.99 | ||
| Q3 24 | $-0.15 | $-1.17 | ||
| Q2 24 | $-0.12 | $-1.05 | ||
| Q1 24 | $-0.08 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $22.9M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $93.6M | $102.7M |
| 总资产 | $132.1M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DIBSRGNX
| Q4 25 | $22.9M | $230.1M | ||
| Q3 25 | $19.9M | $274.2M | ||
| Q2 25 | $22.4M | $323.3M | ||
| Q1 25 | $20.3M | $267.9M | ||
| Q4 24 | $26.0M | $234.7M | ||
| Q3 24 | $22.0M | $255.5M | ||
| Q2 24 | $23.8M | $290.4M | ||
| Q1 24 | $33.7M | $338.7M |
股东权益DIBSRGNX
| Q4 25 | $93.6M | $102.7M | ||
| Q3 25 | $94.0M | $161.5M | ||
| Q2 25 | $94.9M | $213.7M | ||
| Q1 25 | $96.2M | $274.2M | ||
| Q4 24 | $99.3M | $259.7M | ||
| Q3 24 | $107.2M | $301.4M | ||
| Q2 24 | $110.4M | $348.3M | ||
| Q1 24 | $131.0M | $390.7M |
总资产DIBSRGNX
| Q4 25 | $132.1M | $453.0M | ||
| Q3 25 | $135.2M | $525.2M | ||
| Q2 25 | $138.6M | $581.0M | ||
| Q1 25 | $142.5M | $490.9M | ||
| Q4 24 | $145.8M | $466.0M | ||
| Q3 24 | $154.4M | $519.1M | ||
| Q2 24 | $157.6M | $569.4M | ||
| Q1 24 | $179.5M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.3M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $3.6M | $-52.8M |
| 自由现金流率自由现金流/营收 | 15.7% | -174.0% |
| 资本支出强度资本支出/营收 | 2.9% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-3.2M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流DIBSRGNX
| Q4 25 | $4.3M | $-52.3M | ||
| Q3 25 | $-1.5M | $-56.0M | ||
| Q2 25 | $-5.1M | $-49.3M | ||
| Q1 25 | $-96.0K | $33.6M | ||
| Q4 24 | $2.8M | $-31.6M | ||
| Q3 24 | $-3.0K | $-40.5M | ||
| Q2 24 | $-2.6M | $-45.5M | ||
| Q1 24 | $-3.1M | $-55.5M |
自由现金流DIBSRGNX
| Q4 25 | $3.6M | $-52.8M | ||
| Q3 25 | $-1.5M | $-56.5M | ||
| Q2 25 | $-5.2M | $-49.7M | ||
| Q1 25 | $-143.0K | $32.6M | ||
| Q4 24 | $1.5M | $-32.7M | ||
| Q3 24 | $-44.0K | $-40.9M | ||
| Q2 24 | $-3.0M | $-46.0M | ||
| Q1 24 | $-3.3M | $-56.0M |
自由现金流率DIBSRGNX
| Q4 25 | 15.7% | -174.0% | ||
| Q3 25 | -6.8% | -189.9% | ||
| Q2 25 | -23.4% | -232.8% | ||
| Q1 25 | -0.6% | 36.6% | ||
| Q4 24 | 6.5% | -154.2% | ||
| Q3 24 | -0.2% | -168.9% | ||
| Q2 24 | -13.5% | -206.2% | ||
| Q1 24 | -14.8% | -358.5% |
资本支出强度DIBSRGNX
| Q4 25 | 2.9% | 1.7% | ||
| Q3 25 | 0.1% | 1.7% | ||
| Q2 25 | 0.2% | 1.8% | ||
| Q1 25 | 0.2% | 1.2% | ||
| Q4 24 | 5.8% | 5.1% | ||
| Q3 24 | 0.2% | 1.3% | ||
| Q2 24 | 1.6% | 2.1% | ||
| Q1 24 | 0.9% | 3.6% |
现金转化率DIBSRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DIBS
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
